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Xiance Jin1, Weigang Hu2, Haijiao Shang3, Ce Han1, Jinling Yi1, Yongqiang Zhou1 and Congying Xie1*Abstract
Objective: To investigate the anatomic and dosimetric variations of volumetric modulated arc therapy (VMAT) in
the treatment of nasopharyngeal cancer (NPC) patients based on weekly cone beam CT (CBCT).
Materials and methods: Ten NPC patients treated by VMAT with weekly CBCT for setup corrections were reviewed
retrospectively. Deformed volumes of targets and organs at risk (OARs) in the CBCT were compared with those in
the planning CT. Delivered doses were recalculated based on weekly CBCT and compared with the planned doses.
Results: No significant volumetric changes on targets, brainstem, and spinal cord were observed. The average
volumes of right and left parotid measured from the fifth CBCT were about 4.4 and 4.5 cm3 less than those from
the first CBCT, respectively. There were no significant dose differences between average planned and delivered
doses for targets, brainstem and spinal cord. For right parotid, the delivered mean dose was 10.5 cGy higher
(p = 0.004) than the planned value per fraction, and the V26 and V32 increased by 7.5% (p = 0.002) and 7.4%
(p = 0.01), respectively. For the left parotid, the D50 (dose to the 50% volume) was 8.8 cGy higher (p = 0.03) than
the planned values per fraction, and the V26 increased by 8.8% (p = 0.002).
Conclusion: Weekly CBCTs were applied directly to study the continuous volume changes and resulting dosimetric
variations of targets and OARs for NPC patients undergoing VMAT. Significant volumetric and dosimetric variations
were observed for parotids. Replanning after 30 Gy will benefit the protection on parotids.
Keywords: CBCT-based dose calculation, Deformable image registration, Volumetric modulated arc therapy,
Nasopharyngeal cancer, Adaptive replanningDue to its sharp dose gradient, intensity modulated
radiotherapy (IMRT) has been accepted as the primary
treatment modality for nasopharyngeal cancer (NPC)
patients [1,2]. Studies have confirmed that the dosimet-
ric advantages of IMRT over conventional treatment
translated into clinical outcomes with reduced parotid
toxicity [3]. However, geometry and anatomic changes
during the long course of IMRT treatment have limited
the clinical benefits of IMRT [4].* Correspondence: wzxiecongying@163.com
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stated.Onboard cone beam CT (CBCT) has been applied to re-
solve the critical aspects of IMRT, such as patient setup
and target localization [5]. The CBCT using a kilovoltage
(kV) imaging system mounted on a linear accelerator has
emerged as a significant technique for registering the soft
tissue [6]. Anatomic changes in head and neck cancer pa-
tients throughout the radiation therapy treatment course
due to tumor shrinkage, body weight loss, and soft tissue
changes have been reported [7,8]. Daily CBCT for setup
purposes during image-guided radiotherapy (IGRT) has
been conducted to assess the soft tissue changes [9,10].
However, dosimetric variation and accuracy are more
of concern during the radiotherapy course. The feasibility
and accuracy of applying CBCT-based dose calculationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lem of CBCT images [11].
Weekly computed tomography images during IMRT in
the treatment of head and neck patients have been
conducted to study the spatial variability and dosimetric
differences between planned and delivered dose [12,13].
However, rescanning and replanning with weekly CT are
not favored because of the time consuming and additional
machine occupancy [14]. Weekly CBCT employed directly
for dosimetric verification for IMRT or VMAT in the
treatment of NPC patients is a promising solution.
In a previous study, we had achieved reasonable dose
calculation accuracy for head-and-neck cancer patients
based on CBCT with a region of interest (ROI) mapping
method [15]. The purpose of this study is to evaluate the
anatomic changes and related dosimetric effect based on
weekly CBCT directly for NPC patients undergoing
volumetric modulated arc therapy (VMAT) treatment.
Materials and methods
Patient characteristics and planning
This study was approved by the Institutional Review Board
and performed at the 1st Affiliated Hospital of Wenzhou
Medical University. We retrospectively reviewed 10 con-
secutive NPC patients treated by dual arc VMAT between
January 2011 and November 2012 with weekly CBCT for
setup error corrections. All the patients had diagnosed
NPC with various AJCC stages, as summarized in Table 1.
Five patients received induction chemotherapy with pacli-
taxel and cisplatin. One was treated by concurrent chemo-
therapy with paclitaxel, and the other four were treated
by radiotherapy only. Patients were immobilized with a
thermoplastic head mask and scanned on a planning kilo-
voltage CT scan (Philips Medical Systems, Eindhoven, The
Netherlands) with a 3-mm slice thickness.
Target and normal tissue delineations have been re-
ported in our previous study and generalized here only
briefly [16]. Gross tumor volume (GTV) was delineated
as the mass shown in the enhanced CT images and/orTable 1 Characteristics of NPC patients
Patients Sex Age Stages
1 M 48 T4N1M0
2 M 63 T2bN2M0
3 M 71 T3N0M0
4 M 59 T3N1M0
5 M 71 T2bN1M0
6 F 66 T1N1M0
7 M 55 T2bN1M0
8 M 39 T3N2M0
9 M 48 T2bN3bM0
10 M 62 T1N1M0MRI images, including the nasopharyngeal tumor, retro-
pharyngeal lymphadenopathy, and enlarged neck nodes.
The clinical target volume (CTV) was defined as the
GTV plus a margin of potential microscopic spread,
encompassing the inferior sphenoid sinus, clivus, skull
base, nasopharynx, ipsilateral parapharyngeal space, and
posterior third of the nasal cavity and maxillary sinuses.
High-risk nodal regions, including the bilateral upper
deep jugular nodes, submandibular nodes, jugulodigas-
tric, mid-jugular, low jugular, and supraclavicular nodes
and the posterior cervical nodes were included. The
planning target volume (PTV) was created by adding a
3 mm margin to the CTV to account for setup variabil-
ity. Prescription doses were 70 Gy and 56 Gy for GTV
and CTV in 28 fractions, respectively. OARs consisting
of the brainstem, spinal cord, left and right parotids were
constrained for optimization.
Dual arc VMAT plans were generated on Philips
Pinnacle3 treatment planning system (TPS) (clinical ver-
sion 9.2; Philips, Fichburg, WI,USA). Optimization param-
eters and process have been reported in our previous
study [17]. Briefly, the first arc rotates clockwise with a
start angle of 181° and a stop angle of 180°, and the second
arc rotates counterclockwise from 180° to 181°. During
the optimization, leaf motion of 0.46 cm/deg and a final
arc space degree of 4 were employed.
CBCT imaging and number to density curve calculation
VMAT plans were delivered on an Elekta Synergy linac
(Elekta Ltd., Crawley, UK) which integrated an onboard
kV-CBCT. CBCT images were acquired at the first treat-
ment day (CBCT 1) with patients in the treatment
position prior to radiation delivery, and then performed
weekly after. The acquisition parameters were 120 kV,
25 mA, 40 ms per projection with F0 filter. A total of
about 650 projections were acquired for a full rotation
in about 2 min. S20 collimator cassette was used on all
patients giving a nominal irradiated scan length at the
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was used to generate the CBCT number to physical elec-
tron density conversion curve for the dose calculation
with a phantom, Catphan-600 module CTP503 (Phantom
Laboratory, NY) [18]. This process has been reported in
our previous study [15] and summarized here: (1) register
the planning CT images and kV-CBCT images in the
Pinnacle TPS; (2) map the ROIs from conventional CT
dataset to the CBCT dataset, and record the mean CBCT
number values of these ROIs, and (3) Generate the kV-
CBCT numbers to physical electron density calibration
curve based on the density values measured on the con-
ventional CT. The typical CT number to density curves
for CT and CBCT were presented in Figure 1.
Volumetric and dosimetric evaluation
Volumetric changes and resulting dosimetric effects based
on CBCT images were investigated using the Raystation
TPS (version 3.5, RaySearch, Stockholm, Sweden). The
Raystation TPS was commissioned with the same beam
data as the Pinnacle system. The dose deviations between
Raystation and Pinnacle were within 1.5% during the com-
mission process. All VMAT plans with initial CT data
were exported from Pinnacle TPS to Raystation TPS
through DICOM service and the dose distributions were
recalcuated based on the same CT number to density cali-
bration curve. Weekly CBCT images were also imported
into the Raystation TPS through DICOM service. For each
patient, each weekly CBCT image was rigidly registered to
the planning CT individually. The rigid registration was
performed automatically and final manual adjustment was
used for better alignment. After the rigid registration, a
deformable registration was also performed automatically
using vertex-vertex correspondence between the reference
image set and the target image sets. That is the user can
convert an region of interest (ROI) with contour shape to
a new ROI with triangle mesh shape. The new ROI can beFigure 1 HU to density calibration curves for CT and CBCT.used as controlling ROI, which means that it has the same
number of vertices in all image sets and that it has point-
to-point correspondence for the vertices. As a result, each
weekly CBCT image had one rigid and one deformed
registration to the original planning CT. Auto contours
were conducted for target volumes and OARs on weekly
CBCTs by mapping the contours in the planning CT to
CBCT with the deformable registrations. A physician care-
fully evaluated all contours and corrections were per-
formed if necessary.
For each patient, the beam arrangements and opti-
mization parameters in the initial treatment plan on the
planning CT was directly applied to the weekly CBCTs.
Using the CBCT number to density calibration curve, the
fractional dose based on the weekly CBCT were recalcu-
lated. To compare the planned dose in the initial planning
CT and the delivered dose on weekly CBCT, the dose to
95% (D95) and 90% (D90) of the GTV and CTV, and the
volume of CTV irradiated by 110% of the prescription
dose (V110) were recorded and compared. The dose to
1% (D1) of brainstem and spinal cord, the dose to 50%
(D50) of parotids, the mean dose (Dmean), the volume of
parotids receiving 26 Gy (V26) and 32 Gy (V32) were also
recorded and compared.
Statistical analysis
Descriptive statistics were calculated to characterize the
dosimetric and volumetric changes of targets and OARs.
Comparisons between the planned dose in the initial CT
and recalculated dose based on weekly CBCTs were ana-
lyzed using one-way ANOVA. When an overall signifi-
cant difference was observed, the post hoc Tukey test
was used to determine which pairwise comparisons dif-
fered. All statistical analyses were conducted with SPSS
17.0 software (spss Inc., Chicago, IL). Differences were
considered statistically significant when p < 0.05.
Results
Figure 2 shows the typical planning CT with manual
contours and the weekly CBCT with deformed contours.
Detailed average volume changes for targets and OARs
were listed in Table 2. The average volumes of CTV on
the first CBCT were smaller than those in the planning
CT, however, no statistical difference of volume changes
were observed during the treatment course. There were
also no general trend and significant volume changes for
GTV and brainstem. The average volumes of parotids on
the first CBCT (CBCT 1) before the radiotherapy were
also close to those in the planning CT, but the average
volumes of parotids decreased continuously during the
treatment course. The average volume of the right par-
otid and left parotid measured from the fifth CBCT
(CBCT 5) were about 4.4 and 4.5 cm3 less than those
measured from the CBCT 1, respectively. Individual
Figure 2 Planning CT with manual contours, CBCTs with deformed contours and a typical fusion image.
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Figure 3.
Dosimetric differences resulting from volume changes
and geometrical errors were summarized in Table 3.
There were no significant dose differences between the
average planned dose and recalculated delivered dose for
both GTV and CTV. There were also no significant dif-
ferences to the average maximum dose of brainstem and
spinal cord between planned and delivered doses.
Dose delivered to the parotids demonstrated some
significant differences. Detailed pairwise comparison p
values between planned dose and recalculated CBCT
dose for parotids were presented in Table 4. As pre-
sented in Table 3 and 4, the D50 of right parotid in-
creased significant since CBCT 3 at the 10th fraction
with a dose of 7.1 cGy higher than (p = 0.02) planned
dose per fraction. The mean dose of right parotid was
10.5 cGy higher than (p = 0.004) planned dose per frac-
tion after CBCT 4 at the 15th fraction. The V26 and
V32 of right parotid from CBCT 4 increased by 7.5%
(p = 0.002) and 7.4% (p = 0.01) compared to the plannedTable 2 Average volume changes from the planning CT to th
Volume (cm3) GTV CTV Brains
Planning CT 67.1 ± 58.7 577.0 ± 137.5 27.7 ±
CBCT 1 66.4 ± 59.2 512.3 ± 130.9 27.5 ±
CBCT 2 66.5 ± 58.6 525.2 ± 138.7 28.5 ±
CBCT 3 66.0 ± 57.5 520.6 ± 141.7 27.4 ±
CBCT 4 64.4 ± 57.0 500.9 ± 125.0 26.9 ±
CBCT 5 65.9 ± 57.8 506.6 ± 137.5 26.8 ±values, respectively. The D50 of left parotid was 8.8 cGy
higher than (p = 0.03) planned dose per fraction from
CBCT 4. The V26 of the left parotid from CBCT 4 in-
creased by 8.8% (p = 0.002) compared to the planned
value.
Discussion
Anatomic and dosimetric variations of NPC in radio-
therapy have long been concerns. In this study, relying
on the CBCT-based dose calculation, weekly CBCTs
were applied directly to study the volumetric changes
and resulting dosimetric effects of 10 consecutive NPC
patients underwent VMAT treatment.
Due to the limited field of view, the CBCT may not span
the complete longitudinal dimension of the target volume
for some NPC patients. The calculation grids in the initial
planning CT of two patients were adjusted and shortened
in longitudinal direction to match the target volumes in
the initial CTs and in the CBCTs. The average volumes of
CTV and spinal cord on the first CBCT were smaller than
those in the planning CT. However, except for parotids,e CBCTs
tem Cord Right parotid Left parotid
2.3 13.6 ± 4.7 26.7 ± 6.3 25.7 ± 7.3
2.4 12.5 ± 2.2 24.9 ± 6.9 24.1 ± 6.6
3.7 13.6 ± 5.0 24.0 ± 5.8 23.3 ± 6.8
2.3 12.9 ± 3.3 23.3 ± 5.9 22.2 ± 7.1
2.3 12.6 ± 2.2 22.3 ± 5.7 20.9 ± 6.3
3.5 13.8 ± 3.6 20.5 ± 4.9 19.6 ± 6.2
Figure 3 Volume changes measured with weekly CBCT of a) right parotid and b) left parotid.
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observed based on CBCT 1 in this study. The volume
changes of parotids were unique for each individuals as
shown in Figure 3. According to Table 2, the average
weekly shrinkage of right and left parotids were 4.4% and
4.7%, respectively. This was close to the reported glands
shrinkage of 4.9%/wk in the study of Robar et al., in which
weekly CT was applied to study the spatial variability of
OAR and the resultant dosimetric effects during IMRT for
15 head and neck patients [12].Table 3 Dosimetric differences between planned dose and de
Planned dose CBCT1 CBCT2
GTV
D95 (cGy) 228.6 ± 3.8 230.1 ± 5.0 227.8 ± 6.8
D90 (cGy) 233.2 ± 3.6 235.0 ± 5.1 231.6 ± 7.5
CTV
V110 29.3 ± 13.0 32.0 ± 14.0 28.9 ± 14.3
D95 (cGy) 188.6 ± 3.0 189.9 ± 4.5 188.1 ± 4.7
D90 (cGy) 192.8 ± 2.7 194.5 ± 3.7 192.7 ± 5.4
D1 (cGy)
Brainstem 153.6 ± 11.2 150.1 ± 11.2 150.1 ± 15.8
Cord 130.3 ± 10.4 130.3 ± 6.3 133.7 ± 16.2
Right parotid
D50 (cGy) 74.5 ± 3.4 79.9 ± 5.0 77.8 ± 4.5
Dmean (cGy) 95.6 ± 5.4 101.9 ± 5.3 99.1 ± 6.4
V26 36.5 ± 3.0 41.5 ± 3.8 38.9 ± 4.3
V32 29.3 ± 4.9 33.7 ± 4.7 31.2 ± 5.2
Left parotid
D50 (cGy) 74.9 ± 2.6 80.0 ± 3.7 77.3 ± 5.7
Dmean (cGy) 94.8 ± 8.1 101.4 ± 10.2 99.6 ± 8.2
V26 34.8 ± 3.3 39.8 ± 5.3 39.0 ± 2.7
V32 27.5 ± 5.5 31.2 ± 6.7 31.2 ± 5.7Currently, the design of onboard CBCT is far from op-
timal and its quality is adversely influenced by many fac-
tors, such as scatter, beam hardening and intra-scanning
organ motion. The question of whether CBCT images
can be used directly for radiation dose calculation has
been raised and investigated. Based on reliable CBCT
HU and density calibration curve, studies have demon-
strated the reliability and accuracy of CBCT-based dose
calculation [19,20]. Our previous study also demon-
strated that ROI mapping method was an effective andlivered dose calculating from CBCT
CBCT3 CBCT4 CBCT5 p
226.6 ± 6.3 228.5 ± 7.1 230.3 ± 9.9 0.83
224.6 ± 23.3 232.9 ± 7.1 227.1 ± 23.4 0.57
28.8 ± 13.9 30.3 + 14.7 30.1 + 14.2 1.00
187.5 ± 4.5 188.0 ± 4.5 189.1 ± 5.0 0.86
193.1 ± 4.9 193.0 ± 4.8 194.6 ± 3.3 0.83
151.6 ± 17.4 149.7 ± 16.6 152.1 ± 16.8 1.00
133.4 ± 11.6 130.5 ± 13.6 137.3 ± 16.0 0.79
81.6 ± 5.3 82.8 ± 6.2 82.2 ± 3.7 0.002
102.6 ± 6.8 106.1 ± 8.0 101.2 ± 4.4 0.012
41.3 ± 5.0 44.0 ± 4.5 42.3 ± 3.5 0.003
35.3 ± 5.2 36.7 ± 4.6 36.0 ± 4.0 0.006
76.4 ± 9.2 83.7 ± 7.3 82.0 ± 6.3 0.017
101.9 ± 7.6 104.6 ± 9.8 103.3 ± 7.6 0.18
40.5 ± 5.5 43.6 ± 6.4 42.9 ± 4.9 0.02
32.7 ± 5.9 35.1 ± 7.2 33.6 ± 7.6 0.17
Table 4 Comparison between planned parotid dose and delivered parotid dose calculated using CBCT
p Planned vs CBCT 1 Planned vs. CBCT 2 Planned vs. CBCT 3 Planned vs. CBCT 4 Planned vs. CBCT 5
Right parotid
D50 (cGy) 0.13 0.64 0.02 0.004 0.01
Dmean (cGy) 0.22 0.80 0.13 0.004 0.34
V26 0.09 0.78 0.11 0.002 0.03
V32 0.32 0.94 0.07 0.01 0.03
Left parotid
D50 (cGy) 0.45 0.95 1.00 0.03 0.13
V26 0.21 0.38 0.11 0.002 0.01
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[15]. Therefore, we applied the same method in this
study to investigate the dosimetric effects during VMAT
based on weekly CBCT directly.
There were no significant differences between the
planned and delivered doses for GTV and CTV. This was
consistent with the study of Zhang et al., in which a plan-
ning CT and weekly repeat CT were scanned to study the
actual dose variability of targets and OARs for 11 NPC pa-
tients during IMRT [21]. The average maximum doses rep-
resented by D1 for the brainstem and spinal cord were not
significant different between planned and delivered doses.
However, patient 1 demonstrated a 16.8% and 26.0% dose
increase for brainstem and spinal cord on CBCT 5, re-
spectively. This indicated a random dosimetric variability
for brainstem and spinal cord similar to the reported re-
sults in the study of Robar et al. [12]. The increased dose
on CBCT 5 could be caused by a dramatic anatomic
changes resulting from a sharp volume shrinkage of pa-
rotids, as shown in Figure 3.
Both parotids shifted towards a greater delivered dose
during the VMAT treatment, which was consistent with
the studies based on weekly CT during IMRT treatment
[12,21]. Compared to the planned dose, the delivered
dose on D50, Dmean, V26 and V32 of parotids were in-
creased significantly after CBCT 4, which was obtained
at the 15th fraction with a dose of 30 Gy and 37.5 Gy
for CTV and GTV, respectively. This implies a replan-
ning after 30 Gy will benefit the parotid protection for
NPC patients during VMAT treatment. However, the
time trend for the dosimetric changes of parotids was
less obvious compared to the time trend of their volume
changes, as shown in Table 3. The small dosimetric fluc-
tuations among CBCTs could be caused by the errors of
CBCT based dose calculation [15]. Another explanation
could be the limited number of patients included in this
study. Additional work on a larger patient population is
warranted to decide the proper adaptive replanning time
for NPC patients.
CBCT and megavoltage CT (MVCT) [4] have been
widely employed during the radiotherapy for geometricerror corrections. Direct dose calculation based on
CBCT and MVCT will certainly provide a more conveni-
ent and straightforward way than weekly repeated CT
images for adaptive replanning [12,13]. However, due to
the intrinsic limitations of CBCT, extensive work on
the reliability and accuracy of CBCT-based dose calcula-
tion is also warranted to evaluate whether our findings
were accurate enough and could actually translate into
guidelines.
Conclusion
CBCT-based dose calculation was applied directly to
study the anatomic changes and resulting dosimetric
variations for NPC patients undergoing VMAT treat-
ment. Continuous volume changes in the parotids were
observed with weekly CBCT. Significant dosimetric vari-
ations in the parotids were presented at 15th fraction
with CBCT 4. No significant difference in volumetric
and dosimetric variations were observed for other OARs
and targets. A replanning after 30 Gy may be useful in
the VMAT for NPC.
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